company background image
OXB

Oxford Biomedica LSE:OXB Stock Report

Last Price

UK£3.77

Market Cap

UK£362.2m

7D

-4.1%

1Y

-74.4%

Updated

28 Sep, 2022

Data

Company Financials +
OXB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

OXB Stock Overview

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally.

Oxford Biomedica plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oxford Biomedica
Historical stock prices
Current Share PriceUK£3.77
52 Week HighUK£16.08
52 Week LowUK£3.45
Beta0.97
1 Month Change-13.55%
3 Month Change-17.07%
1 Year Change-74.39%
3 Year Change-30.92%
5 Year Change-17.25%
Change since IPO-85.09%

Recent News & Updates

Shareholder Returns

OXBGB BiotechsGB Market
7D-4.1%-5.5%-3.1%
1Y-74.4%-40.1%-14.5%

Return vs Industry: OXB underperformed the UK Biotechs industry which returned -40.1% over the past year.

Return vs Market: OXB underperformed the UK Market which returned -14.5% over the past year.

Price Volatility

Is OXB's price volatile compared to industry and market?
OXB volatility
OXB Average Weekly Movement6.8%
Biotechs Industry Average Movement7.5%
Market Average Movement5.3%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: OXB is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: OXB's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995959Roch Doliveuxhttps://www.oxb.com

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes.

Oxford Biomedica plc Fundamentals Summary

How do Oxford Biomedica's earnings and revenue compare to its market cap?
OXB fundamental statistics
Market CapUK£362.24m
Earnings (TTM)-UK£24.54m
Revenue (TTM)UK£125.57m

2.9x

P/S Ratio

-14.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OXB income statement (TTM)
RevenueUK£125.57m
Cost of RevenueUK£49.68m
Gross ProfitUK£75.89m
Other ExpensesUK£100.43m
Earnings-UK£24.54m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin60.43%
Net Profit Margin-19.54%
Debt/Equity Ratio26.3%

How did OXB perform over the long term?

See historical performance and comparison